Merck & Co. Inc. predicts it will make between $5 billion and $7 billion in sales of its potentially game-changing new oral COVID-19 drug in 2022, assuming it's granted regulatory authorization this year.

from MarketWatch.com - Top Stories https://ift.tt/3vXX2R9
via IFTTT
from MarketWatch.com - Top Stories https://ift.tt/3vXX2R9
via IFTTT
Kommentare
Kommentar veröffentlichen